<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124199">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01670773</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-1004-103</org_study_id>
    <nct_id>NCT01670773</nct_id>
  </id_info>
  <brief_title>A Study of CAT-1004 Biomarkers in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Single Center, Biomarker Study in Healthy Subjects Receiving Single Doses of CAT-1004</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catabasis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catabasis Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess mechanistic blood biomarkers of CAT-1004 in healthy
      humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activity p65 following ex vivo lipopolysaccharide stimulation</measure>
    <time_frame>Pre/post each of 3 Single doses</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <other_outcome>
    <measure>Other biomarkers including select cytokines and RNA gene expression may also be assessed</measure>
    <time_frame>Pre/post each of 3 Single doses</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Assessment of Mechanistic Blood Biomarkers in Healthy Humans</condition>
  <arm_group>
    <arm_group_label>CAT-1004 Dose #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salsalate + DHA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single Dose #3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAT-1004</intervention_name>
    <arm_group_label>CAT-1004 Dose #1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salsalate + DHA</intervention_name>
    <arm_group_label>Salsalate + DHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good health as determined by medical history, vital signs, EGC, physical exam and
             clinical lab results

          -  BMI between 18 and 30 kg/m2 inclusive

        Exclusion Criteria:

          -  Viral or bacterial infection within 21 days prior to randomization

          -  Use of prescription drugs, nonprescription drugs, herbals and dietary supplements
             within 7 days prior to randomization
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Donovan, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Catabasis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ProMedica</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 29, 2012</lastchanged_date>
  <firstreceived_date>August 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sodium Salicylate</mesh_term>
    <mesh_term>Salicylsalicylic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
